Concord Drugs Balance Sheet Health
Financial Health criteria checks 2/6
Concord Drugs has a total shareholder equity of ₹338.2M and total debt of ₹175.2M, which brings its debt-to-equity ratio to 51.8%. Its total assets and total liabilities are ₹588.1M and ₹249.9M respectively. Concord Drugs's EBIT is ₹19.1M making its interest coverage ratio 1. It has cash and short-term investments of ₹1.8M.
Key information
51.8%
Debt to equity ratio
₹175.19m
Debt
| Interest coverage ratio | 1x |
| Cash | ₹1.76m |
| Equity | ₹338.18m |
| Total liabilities | ₹249.89m |
| Total assets | ₹588.06m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 538965's short term assets (₹446.2M) exceed its short term liabilities (₹213.4M).
Long Term Liabilities: 538965's short term assets (₹446.2M) exceed its long term liabilities (₹36.5M).
Debt to Equity History and Analysis
Debt Level: 538965's net debt to equity ratio (51.3%) is considered high.
Reducing Debt: 538965's debt to equity ratio has increased from 42.4% to 51.8% over the past 5 years.
Debt Coverage: 538965's debt is not well covered by operating cash flow (4.5%).
Interest Coverage: 538965's interest payments on its debt are not well covered by EBIT (1x coverage).